Preparing for the FDA’s 2026 Human Factors Requirements

What the May 2026 FDA human factors guidance means for your medical device 510(k) submission

The Food and Drug Administration issued an updated human factors guidance on May 29, 2026, altering the exact documentation medical device developers must submit with their marketing applications. This breakdown explains the new risk-tiered paths to help small engineering teams avoid unnecessary submission holds and protect their launch timelines.

1. What are the new FDA human factors submission categories?

This response profiles the three risk-based reporting tracks that dictate whether your startup faces active simulation testing or a basic file review.

Regulators have established three separate assessment pathways based on potential user risk and the scope of the design modifications. Category 1 applies to minor updates where the changes do not affect the user interface or any part of the device labeling. Category 2 covers changes where your use-related risk file shows that no new tasks capable of causing serious injury are introduced or affected. Category 3 serves as the highest tier, requiring full user validation data to support market clearance.

2. Do we have to redo usability testing if our device changes are small or minor?

Small design changes can often bypass new clinical simulations if they do not change or touch high-consequence user interactions.

Bypassing new validation testing is possible if your updated risk file shows that the design modifications have no impact on safety-relevant steps. However, there is a catch for teams doing rapid software updates. If you make multiple small updates over a window of time, the agency expects you to evaluate those changes collectively rather than trying to file each tiny modification in complete isolation.

3. If we are just modifying an existing medical device, do we really need to build a Comparative Use-Related Risk Analysis (URRA) table?

Modified device submissions require a side-by-side grid comparing the original and updated design to track changes to user hazards.

The requirement depends entirely on what information the new media alters. If you change or add any text, warnings, or graphics used to help manage safety configurations, the agency requires you to evaluate that information to prove that actual users can see and understand the instructions. If the update changes how a user avoids a serious physical injury, it can lead to active testing unless you possess clear proof that your existing design controls remain effective.

4. If we have a small change, like an update to the user manual or a training video to fix a bug, is the FDA going to require additional validation tests?

Modifying any text or graphics related to device safety can trigger additional user testing if it alters how a person avoids a hazard.

The requirement depends entirely on what information the new media alters. If you change or add any text, warnings, or graphics used to help manage safety configurations, the agency requires you to evaluate that information to prove that actual users can see and understand the instructions. If the update changes how a user avoids a serious physical injury, it can lead to active testing unless you possess clear proof that your existing design controls remain effective.

5. What are the big changes between the old 2016 human factors rules and this new May 2026 guidance that are going to impact our engineering timelines and investor milestones?

The updated policy moves past basic design process education to enforce strict file structures and risk-based reporting categories at the time of submission.  

The 2016 FDA human factors guidance document served as a structural textbook explaining how to perform usability work during product development. The new 2026 rules shift focus directly to the filing process, telling you exactly what documents must be placed in your submission based on risk-based tiers. It also formalizes rigid table structures for tracking user hazards that did not exist in the older framework.

6. How does the FDA evaluate what counts as a critical task, and is there a legitimate way to prove our software doesn’t have any so we can avoid testing?

Tasks are judged entirely by the clinical severity of a potential user error, meaning you must prove that mistakes cannot compromise care to avoid testing.

The agency separates these high-risk steps based entirely on the severity of the final clinical outcome, which includes anything that degrades medical treatment or hurts a patient. If an error during use can result in serious injury or death, that step is classified as a high-consequence task. The only way to prove your software has none is to establish through an early risk file that no possible user action, confusion, or omission can lead to a hazardous situation.

7. We already built our usability file to meet European CE Mark standards (IEC 62366-1). Can we just copy-paste that data to satisfy the FDA’s 2026 rules?

European records cannot be transferred directly to a US application without restructuring data tables and accounting for domestic user demographics. 

Moving data directly from an EU MDR Technical File will not pass a US reviewer. While the international standard outlines a similar engineering process for design validation, the FDA has specific documentation templates that must appear in your application. More importantly, the FDA expects validation test results to come from participants who represent the United States user population, meaning foreign datasets are rarely accepted.

8. What human factors documentation mistakes will trigger an automatic Refuse to Accept (RTA) and instantly kill our submission?

Generating risk files after testing is completed or omitting required technical rationales will result in immediate administrative holds. 

Building your design files after the fact is a major error that will stop your application. If a reviewer notices that your use-related risk files were generated long after your engineering validation was completed, it shows a lack of design control and can disrupt your timeline. Additionally, leaving out the newly required summary sections or failing to provide a clear technical justification when trying to qualify for a lower submission category can cause an immediate administrative hold.

Key Takeaways for 2026 Submissions

• Human factors data reporting is now divided into three separate tracks that establish the specific contents of your application before a detailed review begins.
• Incremental design updates completed over a period of time are reviewed as a combined group to verify that consecutive small modifications do not bypass necessary validation steps.
• Modified device applications must feature side-by-side comparative grids that connect layout adjustments directly to your current safety features.
• Technical arguments for skipping a simulation test must be backed by historical real-world data or clear engineering proof.
• Usability reporting parameters and data structures align directly with the recent quality management system regulation updates.

If you find yourself asking multiple follow-up questions about how these tiers apply to your specific device, it is a clear sign that the regulatory path has reached a level of complexity that requires human oversight. While a startup team can plan these strategic steps, a successful submission requires specialized execution. The human engineering group at MedLaunch specializes in physically building and validating these files to protect your launch timeline. Contact MedLaunch today for guidance.

Tags: medical device regulatory compliance, regulatory compliance, risk management